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        INTRODUCTION  
  Airway surface liquid (ASL) composition and volume 
are tightly regulated to maintain mucociliary clearance 
and healthy lung function. Contributions to the ASL com-
position and thickness come from both surface epithelia 
and submucosal glands, with the glands thought to be 
the predominant source of secreted fl  uid and peptides 
for innate defense (  Wang et al., 2001  ;   Wine, 2006  ). Elec-
trolyte transport across the surface epithelium, together 
with accompanying osmotic water fl  ow, determines the 
height of the ASL (  Tarran et al., 2001  ), and this in turn 
determines the effi  ciency of mucociliary clearance. Sev-
eral recent studies have implicated basal or constitutive 
CFTR activity in calcium-mediated gland secretion (  Song 
et al., 2006  ;   Ishibashi et al., 2008  ), modulation of ASL 
pH (  Song et al., 2006  ), and surface epithelial electro-
lyte transport (  Wang et al., 2005  ). 
  Correspondence to Carol A. Bertrand: c  b  e  r  t  r  a  @  p  i  t  t  .  e  d  u   
  Abbreviations used in this paper: ASL, airway surface liquid; CF, cystic 
fi   brosis; DIDS, 4,4'-diisothiocyanatostilbene-2,2' disulfonic acid; GFP, 
green fl  uorescent protein; HBE, human bronchial epithelial; Im, mem-
brane current; IP, immunoprecipitation; IR, inward-rectifi  ed/rectifi  ca-
tion; OR, outward-rectifi  ed/rectifi  cation; R  IV  , I-V ratio; Rm, membrane 
resistance; RP, reverse transcriptase; wt, wild-type.   
  Evidence for constitutive activity of CFTR in airway 
epithelia has a long history:   Smith and Welsh (1992)   
noted a substantial baseline (non-cAMP  –  stimulated) 
apical anion effl  ux in their studies to evaluate the bi-
carbonate permeability of CFTR. Since then, constitu-
tive currents have been noted in human bronchial 
(  Coakley et al., 2003  ) and nasal (  Paradiso et al., 2003  ) 
epithelial cultures, as well as the serous cell model of 
Calu-3 cells (  Krouse et al., 2004  ). These studies attrib-
uted the basal chloride currents to constitutive CFTR 
activity, due primarily to their absence in cystic fi  brosis 
(CF) epithelia. 
  After the discovery of the higher specifi  city CFTR chan-
nel blockers CFI172 and GlyH-101 (  Ma et al., 2002  ; 
  Muanprasat et al., 2004  ), several studies have confi  rmed 
that basal chloride currents were sensitive to these agents, 
reinforcing the hypothesis of constitutive CFTR activity. 
In addition, a role for basal anion secretion in maintain-
ing the ASL pH was proposed by   Song et al. (2006)   
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pression system and human bronchial epithelial (HBE) 
cells from both non-CF and CF donors to address 
these questions. 
  MATERIALS AND METHODS  
  Cell culture 
  HEK 293 cells were propagated in Falcon culture fl  asks (75 cm 
2  ) 
in a humidifi  ed atmosphere of 95% air, 5% CO  2   at 37  °  C. The cells 
were fed twice per week with Dulbecco  ’  s modifi  ed Eagle  ’  s me-
dium supplemented with 10% heat-inactivated fetal bovine serum 
and 2 mM   l-  glutamine. Cells were removed from fl  asks after treat-
ment with TrypLE Express and aliquoted into 6-well plates at high 
density to achieve 98% confl  uence within 24 h, per the standard 
Lipofectamine 2000 transfection protocol (Invitrogen; see below). 
Transfection media were replaced with normal media after 14 h, 
and transfected cells were removed from the 6-well plates after 
24 h and plated to glass coverslips to be used for patch clamping 
within 18  –  36 h. Both the 6-well plates and the glass coverslips 
were coated with poly-  l  -lysine to promote cell adhesion. All cell 
culture medium was obtained from Invitrogen. 
  HBE cells were cultured from excess pathological tissue after 
lung transplantation and organ donation under a protocol ap-
proved by the University of Pittsburgh Investigational Review 
Board, as described previously (  Devor and Pilewski, 1999  ). In brief, 
cells were propagated in fl  asks to 80  –  90% confl  uency, and then 
transferred to 0.33-cm 
2   Costar Transwell fi  lters. Apical media were 
removed 24 h after seeding, and the fi  lters were grown at an air  –
  liquid interface thereafter. Basolateral media were changed twice 
weekly. Three different wild-type (wt)CFTR patient samples were 
used for short circuit current measurements, and the CF HBE 
cells used were obtained from patients with severe disease and 
were at least heterozygous for the     F508 CF mutation. Filters that 
had been grown at an air  –  liquid interface for at least 2 wk before 
testing demonstrated active cilia. 
  Constructs and transfections 
  HEK 293 cells were transiently transfected 24 h after plating with 
either SLC26A9 or CFTR, or both. SLC26A9 expressed in a pcDNA 
3.1 vector was provided by S. Muallem (University of Texas South-
western Medical Center, Dallas, TX), and the entire construct was 
sequenced to verify that it corresponded to the published 4,815-bp 
isoform (  Lohi et al., 2002  ) of human SLC26A9 (NM_052934). 
SLC26A9 with a myc epitope at the N terminus was prepared by 
excising the cDNA encoding SLC26A9 from pcDNA 3.1 and clon-
ing it into a pcDNA 3 Myc vector (Invitrogen). Both wt and     F508 
CFTR expressed in pcDNA3.1 vectors were as described previously 
(  Sun et al., 2008  ). pMAX green fl  uorescent protein (GFP; Amaxa) 
was used in all transfections to balance total cDNA and identify 
transfected cells. Transfections were performed using the stan-
dard Lipofectamine 2000 protocol (Invitrogen), with 2   μ  g of total 
cDNA and 6   μ  l Lipofectamine 2000 in 2 ml Optimem per well of 
a 6-well plate. Quantities of cDNA typically used were 0.5   μ  g for 
SLC26A9, 1.0   μ  g for CFTR, and suffi  cient pMax GFP to bring the 
total cDNA per transfection to 2.0   μ  g. 
  Several preliminary concentrations of SLC26A9 cDNA alone 
and in combination with 1   μ  g CFTR cDNA were tested in HEK 
293 cells to obtain readily measurable currents for either channel 
at the lowest cDNA dose. Increasing the quantity of SLC26A9 
cDNA from 0.1 to 2.0   μ  g increased the magnitude of the constitu-
tive (basal) currents (not depicted); doses higher than the 0.5   μ  g 
used, when coexpressed with CFTR, produced reductions in mem-
brane resistance (Rm) during forskolin stimulation to levels (  <  10 
times the pipette access resistance) that may compromise voltage 
clamping (see below). 
because the unstimulated tracheal surface epithelium 
was able to alkalinize acidic droplets, and the specifi  c 
CFTR channel blockers CFI-172 and GlyH-101 inhib-
ited this alkalization. Interestingly, the alkalization was 
not improved with forskolin stimulation. In the same 
study, porcine and human submucosal gland secretions 
stimulated with pilocarpine were signifi  cantly acidifi  ed 
when treated with CFTR inhibitors. Porcine small air-
ways also displayed constitutive chloride conductances 
that were GlyH-101 inhibited (  Wang et al., 2005  ); there-
fore, the sensitivity of constitutive chloride secretion to 
specifi  c CFTR inhibitors and its absence in CF airways 
has led to the hypothesis of constitutive CFTR activity. 
However, the absence of a consistent model for this reg-
ulatory mode of CFTR and the role of CFTR as a regula-
tor of other transport pathways (  Schwiebert et al., 1999  ) 
suggest that another anion channel may contribute to 
constitutive secretion across airway epithelia. 
    Ko et al. (2004)   identifi  ed two electrogenic members 
of the SLC26 family, SLC26A3 and SLC26A6, which in-
teract with CFTR when expressed in oocytes and HEK 
293 cells. This has led to a model of reciprocal regula-
tion mediated by a physical interaction between the 
R domain of CFTR and the STAS domain of the SLC26A 
family of anion transporters (  Dorwart et al., 2008  ). The 
PDZ domains of these proteins are also believed to 
tether the transporters in close proximity. Coexpression 
of the STAS domain alone with CFTR increased its open 
probability, and, in a reciprocal manner, coexpression 
of CFTR with SLC26A3 increased its HCO  3  -Cl exchange 
activity. Although electrogenic, these exchangers did not 
generate measurable Cl 
      current when they were ex-
pressed in HEK 293 cells, not an uncommon fi  nding for 
the low turnover rates found in exchange transporters 
(  Hille, 2001  ). 
  The identifi  cation of the lung-specifi  c SLC26A9 ( Lohi 
et al., 2002  ) suggests a potential mechanism for airway 
anion transport that may be coordinated with the activ-
ity of CFTR, based on the model above. The behavior of 
SLC26A9 alone has been reported by two groups.   Xu 
et al. (2005)   stably expressed SLC26A9 in HEK 293 cells 
and observed Cl 
     /HCO  3   
      exchange activity, with some 
Cl 
     -independent HCO  3   
      effl  ux. In contrast,   Dorwart 
et al. (2007)   transiently expressed SLC26A9 in oocytes 
and HEK 293 cells and reported large Cl 
      currents con-
sistent with channel behavior, but minimal HCO  3   
      per-
meability. These results seem divergent, but   Romero 
et al. (2006)   has suggested a model of SLC26A9 having 
both Cl 
      channel and electrogenic exchange activities, 
based on preliminary observations in oocytes. The pos-
sibility that SLC26A9 is a CFTR-regulated chloride chan-
nel raises several signifi  cant questions: Does SLC26A9 
contribute to basal and/or cAMP/PKA-stimulated anion 
currents in airway epithelia? Is it sensitive to CFTR 
inhibitors? Does its activity depend on functional CFTR? 
In the studies reported here, we used the HEK 293 ex-    Bertrand et al.  423
fl  uorescent light source was applied with a manual shutter to per-
mit selection of GFP-labeled cells viewed through a 40  ×   objective. 
Once a cell was selected, the shutter was closed and the remainder 
of the experiment was performed under standard (transmitted 
light) illumination. The cells selected displayed a consistent shape 
and fl  uorescence intensity, as suggested in published guidelines 
for use of the HEK 293 expression system (  Thomas and Smart, 
2005  ). Seal formation was monitored using the seal test mode of 
Clampex. Seal resistances exceeded 8 G  Ω  , and pipette capacitance 
was compensated. After rupture of the seal membrane, whole 
cell parameters were verifi  ed using the membrane test mode of 
Clampex before the start of each experiment. 
  All experiments used a standard protocol that alternated an I-V 
step measurement with a voltage clamp interval at a holding 
  potential of     40 mV. The I-V measurement stepped the holding 
potential from     100 to +100 mV in 20-mV steps, 206 samples per 
step at a 50-  μ  s sampling interval for a total measurement time 
of 120 ms. The voltage clamp measurements were collected at 
200-  μ  s intervals, and both measurements were fi  ltered at 1 KHz 
through the Axopatch amplifi  er fi  lter. Each experiment started 
with a 60-s drug-free voltage clamp to ensure the cells were stable. 
After this interval, all protocols alternated I-V measurements with 
90-s voltage clamp intervals. Single-drug protocols applied drug 
for 3 min, followed by a 3-min washout period for a total protocol 
of 7 min, while two-drug protocols included a second 3-min drug 
application for a total protocol of 10 min. The alternating mea-
surements were automated using the sequence key function in 
Clampex to minimize gaps. 
  NMDG-Cl was used for both the bath and pipette solutions to 
isolate chloride currents. The osmolarity of both solutions was 
measured, and NMDG glutamate was added to the bath solution 
(in mM: 140 NMDG-Cl, 10 HEPES, 1 MgCl  2  , 1.5 CaCl  2  , and 5 glu-
cose, to pH 7.3 with Tris) to generate a 25-mOsm gradient that 
obviated cell swelling (  Worrell et al., 1989  ). The pipette solution 
(in mM: 140 NMDG-Cl, 10 HEPES, 1 MgCl  2  , 5 glucose, and 
1 EGTA, to pH 7.2 with Tris) included 1 mM Mg-ATP and 100   μ  M 
GTP. Pipettes using thin-wall thickness borosilicate glass were 
pulled to tip diameters of 1  –  2   μ  m (access resistance,   <  4 M  Ω  ). 
  Ussing chamber measurements 
  HBE monolayers cultured on fi  lter supports were mounted in 
modifi  ed Costar Ussing chambers, and the cultures were continu-
ously short circuited with an automatic voltage clamp (Dept. of 
Bioengineering, University of Iowa). All experiments were per-
formed at 37  °  C. Transepithelial resistance was measured by apply-
ing a 2.5-mV bipolar pulse every 100 s and calculated using Ohm  ’  s 
law. The I-V relation of     -toxin  –  permeabilized monolayers was 
measured by applying a bipolar pulse of increasing voltage steps 
from 10 to 70 mV at 5-s intervals per step. Each voltage step lasted 
2 s, and the monolayer was short circuited (0 mV) between steps. 
Transepithelial resistance measurements were suspended during 
I-V measurements. Due to the large currents recorded during the 
I-V measurements, electrode stability was closely monitored. 
  For intact monolayer experiments, the bathing Ringer  ’  s solu-
tion was composed of 120 mM NaCl, 25 mM NaHCO  3  , 3.3 mM 
KH  2  PO  4  , 0.8 mM K  2  HPO  4  , 1.2 mM MgCl  2  , 1.2 mM CaCl  2  , and 
10 mM glucose. Chambers were constantly gassed with a mixture of 
95% O  2  /5% CO  2  , which maintained the pH at 7.4. Solutions used 
during     -toxin permeabilization experiments were bicarbonate 
free, and a chloride gradient was established to generate a driving 
force for transepithelial chloride fl  ow. For experiments using a 
mucosal to serosal gradient, the mucosal solution was composed 
of 115 mM NaCl, 25 mM Na-gluconate, 5 mM KCl, 10 mM HEPES, 
1 mM MgCl  2  , and 5 mM glucose, and the serosal solution con-
sisted of 70 mM NaCl, 70 mM Na-gluconate, 5 mM KCl, 10 mM 
HEPES, 1 mM MgCl  2  , and 5 mM glucose, both at pH 7.4. To gen-
erate a serosal to mucosal gradient, the bathing solutions (above) 
  Reverse transcriptase (RT)-PCR and immunoprecipitation (IP) 
  Total RNA was isolated from either HEK 293 cells grown in T25 
fl  asks within 36  –  48 h after transfection, or from HBE cells grown 
on fi  lter supports at air  –  liquid interface for at least 2 wk, using the 
RNAqueous-4PCR kit (Applied Biosystems). HEK cells were dis-
sociated from the fl  ask after a 5-min exposure to TrypLE Express, 
pelleted, and then processed according to the manufacturer  ’  s in-
structions. For HBE fi  lters, monolayers were rinsed with 37  °  C PBS 
(calcium and magnesium-free) and incubated with fresh PBS on 
both the apical and basolateral sides for 5 min to disrupt the tight 
junctions. After aspiration of the apical PBS, 0.25% trypsin EDTA 
(Invitrogen) was added, and monolayers were incubated for 15 
min at 37  °  C. Cells were extracted from the fi  lter with vigorous pi-
petting, pelleted, and then processed according to the kit proto-
col. Three fi  lters were dissociated per sample. Isolated RNA was 
DNase treated and then stored at     80  °  C. 
  Two-step RT-PCR was performed using a RETROscript kit 
(Applied Biosystems). For generation of cDNA,     2   μ  g of the pre-
viously harvested total RNA was reverse transcribed using Oligo(dT) 
primers at an incubation temperature of 42  °  C, per the manufac-
turer  ’  s instructions. The resulting cDNA was stored at     20  °  C 
until PCR was performed. Both total RNA and cDNA were used 
within 1 mo of harvesting and reverse transcription, respectively. 
  The PCR steps were performed with the following primers: 
5    -GAGCAGAGCCCTTTCACACACCTCAGG -3     and 5    -GCCTAT-
CATGTCCTTCCACTGTGAGACCAC-3     for SLC26A9; 5    -AGG-
AGGCAGTCTGTCCTGAA-3     and 5    -CACTGCTGGTATGCTCT-
CCA-3     for CFTR; and a commercial RT-PCR primer kit to detect 
human     -actin (Invitrogen) as a control. The SLC26A9 primers 
cover the region corresponding to both sets of primers used by 
  Lohi et al. (2002)   and include both the 5     UTR and the N-terminal 
coding region of the mRNA; they amplify an 1,100-bp product. 
The CFTR primers amplify a 237-bp product, and the     -actin prim-
ers identify a 353-bp product. The PCR reaction was performed 
according to the RETROscript kit protocol with an annealing 
temp of 55  °  C for both CFTR and     -actin, and 62  °  C for SLC26A9. 
A Robocycler with a temperature gradient block was used to per-
form all the reactions simultaneously using two separate anneal-
ing temperatures. 35 cycles were run. 
  For coimmunoprecipitation studies, HEK 293 cells were tran-
siently transfected with wtCFTR   ±   Myc-SLC26A9. After 48 h, cells 
were briefl  y treated with 10   μ  M forskolin, and then lysed (150 mM 
NaCl, 50 mM HEPES, pH 8.0, 1% Nonidet P-40, 1 mM EDTA, 10% 
glycerol, and protease inhibitors). After disruption of the cells, 
500   μ  g of total proteins was subjected to IP with an anti-Myc 
monoclonal antibody (University of Iowa Hybridoma Center), as 
described previously (  Sun et al., 2008  ). Precipitates were resolved 
by SDS-PAGE, and immunoblots were performed using anti-
CFTR antibody (no. 217; Cystic Fibrosis Foundation Therapeutics, 
http://www.cftrfolding.org/CFFTReagents.htm). 
  Whole cell patch clamping 
  All whole cell patch clamping was performed using a 200B Axo-
patch amplifi  er controlled by Clampex 8.1 software through a 
Digidata 1322A acquisition board (all from MDS Analytical Tech-
nologies). Bath solutions containing the different blockers and/
or stimulants to be applied were distributed among eight separate 
reservoirs of a Valvelink 8 pressurized perfusion system (Automate 
Scientifi  c). Reservoir selection was also controlled by the Clampex 
8.1 software to ensure consistent timing for all experiments. The 
output line from the perfusion system was run through a heated, 
circulating water bath and applied to the imaging chamber at 
2.0 ml/m and 37  °  C. The delay between valve selection and ap-
pearance of the solution at the 300-  μ  l chamber was 20 s. 
  The imaging chamber was mounted on the stage of a Nikon 
  Diaphot microscope equipped with standard illumination and a 
150-W Xenon lamp and GFP fi  lter cube (Ex 485/Em 550). The 424   SLC26A9 IS CONSTITUTIVELY ACTIVE AND REGULATED BY CFTR 
  response in HEK 293 cells was examined (  Figs. S1 and S2  ). In ad-
dition, suitable parameters for     -toxin permeabilization of HBE 
cells were established (  Fig. S3  ). Finally, the effects of additional 
chloride channel blockers on SLC26A9 currents are reported. 
The online supplemental material is available at http://www.jgp
.org/cgi/content/full/jgp.200810097/DC1. 
  RESULTS  
  HBE monolayers demonstrate GlyH-101  –  inhibited 
constitutive currents 
  We initially tested whether the constitutive currents 
observed across our polarized, well-differentiated HBE 
monolayers after amiloride inhibition of sodium trans-
port were sensitive to GlyH-101 inhibition. These experi-
ments were performed using the short-circuit technique 
under standard conditions for HBE monolayers that in-
cluded a bicarbonate-buffered Ringer  ’  s solution in both 
mucosal and serosal compartments and continuous 
aeration with a CO  2  /O  2   mix to maintain pH. After amil-
oride inhibition of ENaC currents, HBE monolayers 
exhibited an average basal current of     13.7   ±   1.2     A/
cm 
2   (  n   = 8;   Fig. 1  ).   Apical addition of 50   μ  M GlyH-101 
rapidly inhibited 44   ±   4% (  n   = 4) of this basal current 
(gray curve). The addition of forskolin to the GlyH-
101  –  blocked monolayer produced a small increase in 
Cl 
      secretion (    Isc =     4.1   ±   1.5     A/cm 
2  ) that was com-
pletely inhibited by basolateral addition of bumetanide; 
basolateral addition of 4,4'-diisothiocyanatostilbene-2,2' 
disulfonic acid (DIDS) had little or no effect on the re-
sidual current. By comparison (black curve), forskolin 
stimulated a larger Cl 
      secretory current (    Isc =     17.7   ±   
were reversed. The mucosal solution for either gradient direction 
also included 1.5 mM CaCl  2   to maintain tight junction integrity. 
  Basolateral membrane permeabilization was accomplished 
using 1   μ  g/ml of   Staphylococcus aureus       -toxin. Because the toxin 
pores are large enough to permit the fl  ow of calcium and ATP 
(  Bhakdi et al., 1993  ), and preliminary experiments demonstrated 
a loss of forskolin-stimulated response in the absence of added 
ATP (  Supplemental text  ), basolateral solutions were nominally 
calci  um free and 1 mM Na-ATP was added to the basolateral solu-
tion. In addition, ouabain was added to the basolateral solution 
after permeabilization commenced to inhibit the NaK-ATPase and 
limit ATP consumption. 
  Data analysis 
  I-V relations are plotted as the average value of the current for the 
duration of each holding potential. Whole cell current tracings were 
reduced 1,000 times using the substitute average method (PClamp) 
for display purposes only. All patch clamp data are normalized by the 
membrane capacitance value recorded for each cell at the start of 
the experiment. For whole cell I-V data with a chloride equilibrium 
potential of 0 mV (symmetrical chloride concentrations), the non-
linearity of the I-V relation was quantifi  ed by calculating the ratio 
(R  IV  ) of currents measured at the   ±  60-mV step (Vstep) potentials: 
  R  IV   = (I   60     mV        I   0     mV  )/(I       60     mV        I   0     mV  ). 
  For HBE monolayer data, the chloride equilibrium potential 
was approximately   ±  10 mV based on the gradient direction. Thus, 
in addition to the voltage step applied during the I-V measure-
ment, an additional 10-mV bias potential exists. The R  IV   calcula-
tions were adjusted to account for this bias: 
  R  IV   = (I   70     mV        I   10     mV  )/(I       50     mV        I   10     mV  ), serosal to mucosal 
gradient; 
  R  IV   = (I   50     mV        I       10     mV  )/(I       70     mV        I       10     mV  ), mucosal to serosal 
gradient. 
  For a subset of experiments, the contribution of the paracellu-
lar pathway to the R  IV   values was subtracted using an estimate of 
the paracellular conductance (G  P  ). To estimate G  P  , the values of 
G  T   and Isc acquired during permeabilization and GlyH-101 block 
were fi  t to a linear relation and, as previously demonstrated, using 
amiloride inhibition of sodium currents (  Yonath and Civan, 1971  ; 
  Wills et al., 1979  ), G  P   was assigned the y-intercept value. The cur-
rent through SLC26A9 alone (I  A9-Vstep  ) recorded in response to 
the voltage steps used in the calculation of R  IV   was then derived 
using the current divider equation: 
  I  A9-Vstep   = I  T-Vstep  (1      G  T-Vstep  /G  P  ), where G  T-Vstep   was calculated 
using Ohm  ’  s law: 
  G  T-Vstep   = (I  T-Vstep        Isc)/Vstep. 
  All results are displayed as means   ±   SEM. To test for signi-
fi  cance, Student  ’  s   t   test was applied. To examine changes in the 
same group of measurements after different treatments, paired   t   
testing was used. P   <   0.05 was considered signifi  cant. 
  Chemicals 
  GlyH-101 was purchased from EMD; both GlyH-101 and gliben-
clamide were prepared as 1,000  ×   stock solutions in DMSO. For-
skolin was prepared in EtOH. Vehicle additions did not produce 
detectable responses in the recordings. Unless otherwise noted, 
all chemicals were purchased from Sigma-Aldrich. 
  Online supplemental material 
  As a basis for these experiments, the behavior of endogenous 
channels and temperature sensitivity of the expressed wtCFTR 
  Figure 1.     Short-circuit current measurements in HBE mono-
layers reveal GlyH-101 inhibition of basal anion secretion. After 
amiloride inhibition of ENaC current, a basal anion current was 
evident. Application of 50   μ  M GlyH-101 to the apical chamber in-
hibited the basal current (gray trace) and attenuated the sub-
sequent response to forskolin. In the absence of GlyH-101 (black 
trace), forskolin stimulated additional anion secretion. Basolat-
eral application of bumetanide inhibited the forskolin-stimulated 
current in both GlyH-101  –  treated and untreated epithelia; only 
the latter were sensitive to basolateral DIDS (see Results). Traces 
representative of four fi  lters from each condition are shown.         Bertrand et al.  425
whole cell patch mode, SLC26A9-transfected HEK 293 
cells displayed an average membrane current (Im) of 
    16   ±   2 pA/pF at a holding potential of     40 mV (used 
for all whole cell voltage clamp measurements), and a 
relatively low initial Rm of 290   ±   40 M  Ω   (  n   = 36). By 
comparison, cells expressing wtCFTR alone had an ini-
tial basal Im of     2.3   ±   0.4 pA/pF with an Rm of 1,200   ±   
100 M  Ω   (  n   = 61), whereas cells transfected with GFP 
alone exhibited an Im of     0.2   ±   0.25 pA/pF and an Rm 
of 2,700   ±   400 M  Ω   (  n   = 12). The constitutive activity of 
HEK 293 cells expressing SLC26A9 alone was main-
tained during the course of a 7-min recording (  Fig. 2 A  ).   
Bath addition of 10   μ  M forskolin had no signifi  cant 
effect on SLC26A9 currents, nor did 100   μ  M ATP (not 
depicted). In addition, the I-V curves for SLC26A9 trans-
fectants were linear, with a reversal potential equivalent 
to the chloride equilibrium potential (  Fig. 2 B  ). HEK 
293 cells transfected with GFP alone were also unrespon-
sive to forskolin (  Fig. 2 A  ) and ATP (not depicted), and 
they typically displayed small currents with a reversal 
potential of     40 mV and a sigmoidal I-V (Supplemen-
tal text), consistent with other studies of this cell line 
(  Thomas and Smart, 2005  ). 
  To quantify the whole cell I-V characteristics of SLC26A9 
and CFTR channels with and without stimulation and 
5.6     A/cm 
2  ;   n   = 4) in the absence of GlyH-101 that 
was substantially inhibited by basolateral addition of 
bumetanide. Unlike the GlyH-101  –  blocked monolayer, 
however, basolateral addition of DIDS blocked a portion 
of the current remaining after bumetanide inhibition, 
reducing the fi  nal current to a level comparable to GlyH-
101  –  inhibited monolayers. These results indicated that 
GlyH-101 signifi  cantly inhibited the constitutive current 
present before forskolin addition, confi  rming prior ob-
servations (  Wang et al., 2005  ). Additionally, they sug-
gested that a portion of the anion secretory response 
in HBE monolayers after NKCC1 block by bumetanide 
may be due to bicarbonate secretion, as basolateral 
DIDS is expected to inhibit multiple basolateral bi-
carbonate entry processes (  Devor et al., 1999  ;   Fischer 
and Widdicombe, 2006  ). 
  SLC26A9 is a constitutively active chloride channel 
  We compared the characteristics of the chloride cur-
rents of SLC26A9 and CFTR expressed in HEK 293 cells 
to determine whether their properties would elucidate 
the basis of the constitutive and regulated currents across 
HBE monolayers. All experiments using HEK 293 ex-
pression were performed with solutions that limited the 
conductive ions to chloride. On establishment of the 
  Figure 2.     HEK 293 cells transiently transfected with 
SLC26A9 exhibit constitutive chloride currents under 
whole cell voltage clamp. (A) Cells transfected with GFP   ±   
SLC26A9 were voltage clamped at     40 mV. A subset of cells 
were stimulated with 10   μ  M forskolin. SLC26A9-expressing 
cells exhibited constitutive chloride currents that were not 
enhanced by forskolin stimulation. Cells expressing GFP 
alone exhibited no signifi  cant basal current or response 
to forskolin. Representative tracings from at least three ex-
periments each are shown. (B) SLC26A9-transfected cells 
exhibited linear I-V relations before, during, and after for-
skolin treatment. I-V curves are for the trace shown in A, 
labeled SLC26A9 + GFP + fsk, recorded at the indicated 
times (solid diamonds). HEK 293 cells transfected with 
GFP alone had negligible currents that did not contribute 
signifi   cantly to the I-V relations of SLC26A9-expressing 
cells (  Supplemental text  ). All current values are normal-
ized by cell capacitance.     426   SLC26A9 IS CONSTITUTIVELY ACTIVE AND REGULATED BY CFTR 
  CFTR channel blockers interact with SLC26A9 
  One of the most specifi  c and rapidly acting CFTR chan-
nel blockers reported to date is GlyH-101 (  Muanprasat 
et al., 2004  ). Unlike most blockers of CFTR, this nega-
tively charged glycine hydrazide occludes the extracel-
lular vestibule of the open CFTR pore, which results in a 
strong inward rectifi  cation (IR) of the CFTR I-V relation 
in the presence of blocker (  Sheppard, 2004  ). Another 
commonly used CFTR channel blocker is glibenclamide; 
the strong OR I-V characteristic observed during gliben-
clamide inhibition of CFTR has been attributed to the 
interaction of this negatively charged blocker with the 
intracellular face of the channel pore (  Schultz et al., 
1999  ;   Sheppard, 2004  ). We measured the magnitude of 
inhibition and I-V relations of these blockers on HEK 
293 expressing either SLC26A9 or CFTR. 
  As summarized in   Fig. 3  , SLC26A9-transfected cells 
demonstrated a rundown in current to 80% of initial 
levels within 3 min of break-in, which then stabilized for 
the duration of the recordings.   The current rundown 
and stabilization was unaffected by the application of 
forskolin (  Fig. 3 B  ). Strikingly, we found that GlyH-101 
was also a potent inhibitor of the constitutive activity of 
SLC26A9 at a concentration (50   μ  M) typically used to 
inhibit CFTR, blocking 71   ±   4% (  n   = 4) of the constitu-
tive current. This inhibition of SLC26A9 exhibited a 
rapid initial phase followed by a slower inhibition, and 
the block was partially reversed, again with two kinetic 
components, during a 3-min washout (  Fig. 4 A  ).   Unlike 
the result with GlyH-101, the addition of 100   μ  M gliben-
clamide to SLC26A9-transfected cells had no signifi  cant 
effect on Im (  Figs. 3 and 4  ), in agreement with the ob-
servations of   Dorwart et al. (2007)  . 
  Importantly, the I-V relation during GlyH-101 inhibi-
tion of SLC26A9 was only mildly IR with an R  IV   of 0.83   ±   
0.02, compared with an R  IV   of 0.42   ±   0.03 (  n   = 3) for 
GlyH-101 inhibition of stimulated CFTR currents (  Fig. 4 B ; 
only the I-V relations in the presence of blocker are 
shown for comparison of their voltage-dependent prop-
erties). These I-V ratios suggest that the interaction 
of GlyH-101 with SLC26A9 is mechanistically different 
from that with CFTR. Although glibenclamide did not 
signifi  cantly inhibit SLC26A9 currents at a holding po-
tential of    40 mV, the R  IV   during its application dropped 
slightly, but signifi  cantly, from 1.06   ±   0.07 to slightly IR 
(0.95   ±   0.02;   n   = 6; paired   t   test; P   <   0.05). Thus, it is pos-
sible that glibenclamide has a weak interaction with 
SLC26A9 that might reach statistical signifi  cance at a 
higher concentration and/or longer duration of appli-
cation. In contrast, glibenclamide inhibition of forskolin-
stimulated HEK 293 cells expressing wtCFTR displayed 
the expected strong OR R  IV   (1.84   ±   0.02; discussed in 
detail below). The inhibitory actions of both blockers 
were compared against untreated or forskolin-treated con-
trols at time points after the initial current rundown, and 
both blockers were prepared in the same concentration 
in the presence of blockers, we calculated an I-V ratio 
(R  IV  ; see Materials and methods) at different time points 
during the measurement protocols. At 60 s after break-
in, SLC26A9-transfected HEK 293 cells had an R  IV   of 
1.00   ±   0.03 (  n   = 18), confi  rming that this constitutively 
active channel exhibited linear (voltage-independent) 
currents in symmetrical chloride solutions. HEK 293 
cells transiently transfected with wtCFTR exhibited an 
initial R  IV   of 1.31   ±   0.05 (  n   = 28), 60 s after break-in. 
This outward-rectifi  ed (OR) I-V relation and small re-
corded current (above) likely refl  ect endogenous HEK 
293 channels that exhibit signifi  cant rundown (Supple-
mental text) because wtCFTR exhibits linear I-V proper-
ties in symmetrical chloride solutions during stimulation 
and maintains a linear R  IV   after returning to baseline 
  after washout of forskolin. 
  Figure 3.     Summary of SLC26A9 current time course and blocker 
effects. (A) HEK 293 cells treated with 50   μ  M GlyH-101 were sig-
nifi  cantly inhibited after 3 min and exhibited a partial recovery af-
ter 3 min of blocker washout. The effect of 100   μ  M glibenclamide 
was not statistically different from the 20% rundown in constitu-
tive current normally observed in untreated cells. (B) The addi-
tion of forskolin during the blocker protocols did not signifi  cantly 
affect either the rundown or blocker effi  cacy. All currents are nor-
malized to their respective basal current (see Results) at break-in. 
*, P   <   0.05 compared against the same time point from unblocked 
cells and for paired   t   test with prior time point. Number of exper-
iments for each case is indicated on the bar groups. A representa-
tive time course and protocol are shown in   Fig. 2 A  .         Bertrand et al.  427
of vehicle (0.1% DMSO). Under the conditions used 
here, the inhibition of current and shift in R  IV   indicate 
that GlyH-101 signifi  cantly inhibits SLC26A9, whereas 
glibenclamide does not. Most importantly, the shift in 
R  IV   on the application of either blocker to SLC26A9 is 
signifi  cantly different from the shift in R  IV   during their 
inhibition of CFTR, providing a fi  ngerprint to uniquely 
identify the two channels. 
  Coexpression of SLC26A9 and wtCFTR enhances 
the response to forskolin 
  Cells coexpressing SLC26A9 + wtCFTR had a basal cur-
rent of     21   ±   3 pA/pF with an Rm of 218   ±   21 M  Ω   
(  n   = 56) on establishment of the whole cell mode; these 
values were not statistically different from cells express-
ing SLC26A9 alone (above). To further assess whether 
an interaction between the channels was occurring 
in this initial unstimulated state, we monitored the 
current rundown, as well as the effects of a 3-min expo-
sure to GlyH-101 or glibenclamide, in the absence of 
forskolin. As shown in   Fig. 5  , there was no difference in 
the rundown or action of the blockers before stimulation 
whether SLC26A9 was expressed alone or with wtCFTR.   
Furthermore, the I-V ratios were essentially unchanged 
  Figure 4.     The CFTR channel inhibitor GlyH-101 in-
hibits SLC26A9. (A) HEK 293 cells transfected with 
SLC26A9 and voltage clamped at     40 mV were exposed 
to either 50   μ  M GlyH-101 or 100   μ  M glibenclamide af-
ter a 60-s stabilization period. GlyH-101 inhibited 50% 
of the constitutive chloride current within seconds 
and an additional 20% over the course of a 3-min ap-
plication. The inhibition was partially reversed after 
3 min of washout, also with two phases of recovery. The 
minor drop in current during application of 100   μ  M 
glibenclamide was statistically insignifi  cant; longer ex-
posure times and/or higher doses were not explored. 
Representative tracings of at least three experiments 
each are shown. (B) Representative I-V behavior of 
SLC26A9 and CFTR in the presence of the indicated 
blockers. SLC26A9-transfected cells displayed a mild IR 
I-V response after 3 min of exposure to either GlyH-101 
or glibenclamide. Cells transfected with wtCFTR, stim-
ulated with 10   μ  M forskolin, and then inhibited with 
50   μ  M GlyH-101 for 3 min displayed a strong IR I-V re-
sponse. SLC26A9 I-V curves are for traces shown in A, 
measured at 240 s (solid diamond). All current values 
are normalized by cell capacitance.     
  Figure 5.     Current and blocker properties in HEK 293 cells 
coexpressing SLC26A9 + wtCFTR are no different before 
forskolin stimulation from cells expressing SLC26A9 alone. 
The number of experiments for each case is included on 
the bar groups. All currents were normalized to their respec-
tive basal current at break-in. *, P   <   0.05 compared with 
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response of CFTR to stimulation. Although the essential 
shape of the response was similar, cells coexpressing 
SLC26A9 and wtCFTR exhibited larger currents that did 
not return to baseline after washout of forskolin. This 
poststimulation current was not due to a delay in CFTR 
recovery; as shown in   Fig. 6 A  , it persisted for 8 min after 
CFTR alone had returned to its prestimulation baseline. 
Coexpressors maintained linear I-V characteristics be-
fore, during, and after stimulation, and cells expressing 
CFTR alone demonstrated linear I-V relations during 
and also after forskolin stimulation (  Fig. 6, B and C  ). 
from those measured for SLC26A9 alone: GlyH-101 in-
duced a mild IR R  IV   (0.84   ±   0.04;   n   = 3), whereas the 
glibenclamide ratio remained linear (1.03   ±   0.07;   n   = 6). 
Neither ratio was statistically different from its paired, 
pre-blocked value or from the ratios measured for 
SLC26A9 alone. 
  As shown in   Fig. 6 A  , cells expressing CFTR + SLC26A9 
or CFTR alone responded to forskolin within 30 s of ad-
dition and reached peak currents in 90   ±   7 s (  n   = 11) or 
98   ±   6 s (  n   = 21), respectively.   However, coexpression of 
wtCFTR with SLC26A9 signifi  cantly modifi  ed the typical 
  Figure 6.     HEK 293 coexpression of SLC26A9 with wtCFTR increases forskolin-stimulated chloride currents over cells expressing CFTR 
alone. (A) Coexpressers (gray) consistently had larger currents than CFTR alone (black) as assessed at four measurement points: the 
basal currents before stimulation (60 s), the transient peak in response to 10   μ  M forskolin (150 s on average), the current plateau in 
the continued presence of forskolin (240 s), and the poststimulation current observed 3 min after forskolin washout (420 s). The post-
stimulation current in the coexpressers did not diminish during extended recordings (extra 8 min, this case). Representative tracings 
of at least three experiments each are shown. I-V measurements were performed at the indicated intervals (solid diamonds). (B) Cells 
expressing CFTR alone displayed the classical linear I-V in response to forskolin, with minimal current before stimulation and after 
forskolin washout. Curves are for black trace shown in A. (C) Cells expressing SLC26A9 + CFTR also displayed a linear I-V in response 
to forskolin; however, the magnitudes were larger and included the constitutive and enhanced poststimulation currents (note scale 
doubled from B). Curves are for gray trace shown in A. (D) Summary of the responses for SLC26A9 and CFTR expressed alone and 
together. Representative tracings are shown in A and   Fig. 2 A  . Fixed measurement points are identifi  ed in A. Peak values were measured 
at the actual peak of each tracing, with average peak times occurring at 150   ±   7 s for SLC26A9 + wtCFTR coexpressors and 158   ±   6 s for 
wtCFTR alone. The value for SLC26A9 alone was measured at 150 s. The SLC26A9 + wtCFTR coexpressor currents exceed the sum of 
the wtCFTR and SLC26A9 individual currents during and after forskolin stimulation (see Results). All current values were normalized 
to cell capacitance; V  H   =     40 mV. *, P   <   0.05 compared with CFTR alone.         Bertrand et al.  429
current of the coexpressors exceeded the current ob-
served for SLC26A9 alone by     55   ±   16 pA/pF. These 
results suggest that an interaction between the channels 
occurred during forskolin stimulation, and that this 
interaction persisted well after forskolin was removed 
(  Fig. 6 A  ). This behavior could result from the mainte-
nance of CFTR in an active state after forskolin washout 
or from an increase in the activity of SLC26A9. 
  Effect of blockers on HEK 293 cells coexpressing SLC26A9 
and wtCFTR 
  We tested the effect of blockers on forskolin-stimulated 
cells and fi  rst verifi  ed published data on the action of 
the blockers on cells expressing wtCFTR alone. The 
time course of the inhibition and corresponding I-V 
curves are shown in   Fig. 7  .   We found that GlyH-101 was 
very effective on wtCFTR alone (  Fig. 7 A  ), inhibiting 
90   ±   2% (  n   = 3; P   <   0.001) of the plateau current within 
  The observations in   Fig. 5   suggested that SLC26A9 
and CFTR channels were functioning independently 
before the addition of forskolin. If the channels contin-
ued to function independently during stimulation, we 
would expect the larger currents of the coexpressors 
(  Fig. 6 A  ) to refl  ect the sum of the currents measured 
from the independent constructs under the same stim-
ulation protocol. We identifi  ed three specifi  c measure-
ment points for comparison and found that this was not 
the case (  Fig. 6 D  ): at the peak of stimulation, coexpres-
sors averaged an additional     97   ±   54 pA/pF, and dur-
ing the current plateau, an additional     67   ±   34 pA/pF 
over the response of CFTR alone. Both increases are 
several times greater than the comparable currents of 
SLC26A9 alone (    12 and     11 pA/pF, respectively). 
Furthermore, although SLC26A9 normally exhibits some 
rundown within 3 min when expressed alone (  Fig. 3 B  ) 
or with unstimulated CFTR (  Fig. 5  ), the poststimulation 
  Figure 7.     Responses of forskolin-stimulated currents to blockers in HEK 293 cells expressing wtCFTR   ±   SLC26A9. (A) HEK 293 cells 
expressing wtCFTR alone were stimulated with forskolin and allowed to reach a plateau, and then inhibited with either glibenclamide 
or GlyH-101; the latter rapidly and almost completely inhibited wtCFTR alone. V  H   =     40 mV. (B) I-V curves measured 90 s after the 
addition of blocker (330 s in A) demonstrate the opposite voltage dependence of the two blockers. (C) HEK 293 cells coexpressing 
SLC26A9 and wtCFTR were stimulated with forskolin and allowed to reach a plateau, and then inhibited with either glibenclamide or 
GlyH-101. V  H   =     40 mV. (D) The I-V curves measured 90 s after the addition of blocker (330 s in C) demonstrate the opposite voltage 
dependencies of the two blockers. The nonlinearity or voltage dependence of the block of wtCFTR alone (B) is greater than evidenced 
in the coexpressors (see   Table I   for mean values).     430   SLC26A9 IS CONSTITUTIVELY ACTIVE AND REGULATED BY CFTR 
are consistent with a physical interaction between 
stimulated CFTR and SLC26A9, as was demonstrated 
for wtCFTR and SLC26A3 (  Ko et al., 2002, 2004      ). Re-
versing the order of treatment (blocker for 3 min, 
then forskolin stimulation for 3 min in the continued 
presence of blocker) resulted in the same fi  nal R  IV   val-
ues (  Table I  ). 
  With clearly defi  ned  R  IV   values for SLC26A9 and 
CFTR expressed alone and together, we tested the ef-
fect of GlyH-101 inhibition on the poststimulation cur-
rent evident in the coexpressors after forskolin washout 
(  Fig. 6, A and D  ). As shown in   Fig. 8  , HEK 293 coexpres-
sors were fi  rst stimulated with forskolin for 3 min, and 
then perfused with forskolin-free solution for 3 min 
to establish the poststimulation current (295   ±   57% 
of basal current;   n   = 11).   Cells were then treated with 
GlyH-101 for 3 min, which significantly blocked the 
poststimulation current (73   ±   10%;   n   = 3; P   <   0.05). 
1 min of addition. Glibenclamide inhibition was slower to 
develop, most likely due to its intracellular binding site, 
and it was less effective, inhibiting 52   ±   10% (  n   = 4) of 
the plateau current (both 3 min after addition). The I-V 
relations during inhibition (  Fig. 7 B  ) demonstrate sig-
nifi  cant differences in the voltage dependence of block. 
Applying the same protocol to cells coexpressing SLC26A9 
and wtCFTR (  Fig. 7 C  ), we also found that both blockers 
inhibited the plateau current within 2 min of addition. 
GlyH-101 acted more rapidly and inhibited 65   ±   3% 
(  n   = 4) of the plateau current, whereas glibenclamide 
inhibition was slower to develop and blocked 36   ±   11% 
(  n   = 3) of the plateau current. The I-V relations (  Fig. 7 D  ) 
demonstrated the expected inward and OR profi  les for 
GlyH-101 and glibenclamide block, respectively; however, 
the voltage dependence of the inhibition was decreased 
compared with CFTR alone (  Fig. 7 B  ; see quantitation in 
  Table I  , discussed below)  . 
  To assess the individual contributions of coexpressed 
SLC26A9 and wtCFTR to the increased current response 
to forskolin (  Fig. 6 D  ), we measured the R  IV   under dif-
ferent blocker conditions and compared them to the 
R  IV   measured for cells expressing the channels individu-
ally. As reported above and summarized in   Table I  , cells 
expressing SLC26A9 alone demonstrated a slight IR 
during application of either blocker, whereas cells ex-
pressing CFTR alone demonstrated strong IR (GlyH-101) 
and OR (glibenclamide) I-V relations during inhibition. 
In addition, the R  IV   values during blocker inhibition of 
coexpressors before forskolin stimulation were the same 
as for SLC26A9 alone (0.84   ±   0.04,   n   = 3 for GlyH-101; 
1.03   ±   0.07,   n   = 6 for glibenclamide), as was also shown 
for the current magnitudes (  Fig. 5  ). In the presence of 
forskolin, the R  IV   values for the blocked currents were 
intermediate between the values measured for SLC26A9 
alone and wtCFTR alone, suggesting that both channels 
were contributing to the total stimulated current ob-
served in the coexpressors. Similarly, although GlyH-101 
inhibited 90   ±   2% of the forskolin-stimulated CFTR-
alone current, it was less effective on the constitutive 
SLC26A9 current (71   ±   4%) and the forskolin-stimulated 
current in the coexpressors (65   ±   3%). These results 
  TABLE I  
  Comparison of blocker impact on R  IV   for all HEK 293 constructs 
Drug order 
    —    —    —    –   
  Construct
Basal   
a   Forskolin GlyH-101 Forskolin 
  +GlyH-101
Forskolin 
  +Glibenclamide
GlyH-101 
  +Forskolin
Glibenclamide 
  +Forskolin
SLC26A9 0.98   ±   0.03 0.96   ±   0.04 0.85   ±   0.02 0.83   ±   0.02 0.95   ±   0.02 nt   
b   nt
wtCFTR 1.30   ±   0.05 0.98   ±   0.01 0.96   ±   0.04   
c   0.42    ±   0.03 1.84   ±   0.02 0.35   ±   0.01 1.82   ±   0.03
SLC26A9 + 
wtCFTR
1.04   ±   0.04 0.99   ±   0.01 0.84   ±   0.04 0.62   ±   0.05 1.41   ±   0.10 0.50   ±   0.07 1.40   ±   0.09
Order of agonist or blocker represents experimental additions. Each measurement represents an   n     ≥   3.
   
a    Basal values given are for cells subsequently exposed to forskolin.
   
b    nt, not tested.
   
c    CFTR was inactive with Im =     0.09   ±   0.27 pA/pF.
  Figure 8.     GlyH-101 blocks the poststimulation current in HEK 
cells coexpressing SLC26A9 and wtCFTR. Cells were stimulated 
with 10   μ  M forskolin for 3 min, and then perfused with bath 
alone for an additional 3 min to expose the poststimulation cur-
rent. After the poststimulation current had stabilized, 50   μ  M 
GlyH-101 was added for 3 min, after which cells slowly recovered 
from blocker. The effect of GlyH-101 was similar to its effect on 
cells expressing SLC26A9 alone (  Fig. 4 A  ). V  H   =     40 mV, and cur-
rents are normalized to cell capacitance. A representative tracing 
of three experiments is shown.         Bertrand et al.  431
Washout of the blocker resulted in a small recovery of 
the poststimulation current, reminiscent of the par-
tial reversal of the GlyH-101 block in cells expressing 
SLC26A9 alone (  Fig. 4 A  ). The R  IV   during block of the 
poststimulation current was 0.83   ±   0.03 (  n   = 3), identi-
cal to the value obtained for GlyH-101 block in cells ex-
pressing SLC26A9 alone (  Table I  ). Thus, the action of 
GlyH-101 on the poststimulation current in coexpres-
sors was the same as its action on the constitutive cur-
rent of SLC26A9 alone: 70% inhibition with an R  IV   
of 0.83. These results suggest that the enhanced post-
stimulation current was due to SLC26A9, rather than 
to a continued activation of CFTR in the absence of 
forskolin. However, as shown in   Fig. 6 D  , the poststimu-
lation current of the coexpressors was signifi  cantly greater 
than in cells expressing SLC26A9 alone. Either forskolin 
stimulation in coexpressors recruited additional SLC26A9 
channels to the plasma membrane, or the open proba-
bility of SLC26A9 increased in the presence of phos-
phorylated CFTR and persisted after CFTR itself had 
inactivated. Any change in the properties of SLC26A9 
required an interaction with CFTR because forskolin 
had no impact on the extended currents of SLC26A9 
expressed alone (  Figs. 2 and 3  ). 
  Thus far, our results have demonstrated that SLC26A9 
alone was suffi  cient to generate basal currents, that 
SLC26A9 was substantially inhibited by the CFTR blocker 
GlyH-101, that cells coexpressing SLC26A9 and wtCFTR 
exhibited both basal currents and enhanced forskolin-
stimulated currents, and that the contribution of these 
channels to the basal and stimulated currents could 
be differentiated by measurement of the whole cell R  IV   
during blocker treatments. As shown in   Fig. 1  , HBE 
monolayers exhibit a basal current after inhibition of 
sodium transport and in the absence of cAMP/PKA 
stimulation. Previously, this basal current has been at-
tributed to a constitutive activity of CFTR, in part because 
it is absent in HBE cells from CF patients. Interestingly, 
and also in support of a basal activation of CFTR, it was 
demonstrated that this basal activity was inhibited by 
GlyH-101 (  Wang et al., 2005  ;   Song et al., 2006  ), and that 
this inhibition had an impact on ASL composition. Our 
results in HEK 293 cells support a potential role for 
SLC26A9 in generating the basal currents observed in 
HBE monolayers. 
  HBE cells express SLC26A9 mRNA 
    Lohi et al. (2002)   have reported the expression of 
SLC26A9 in airway surface epithelia. We used RT-PCR 
to confi  rm that the primary HBE cells used in these 
protocols expressed SLC26A9, as well as to examine its 
expression in HBE cells from CF patients. RNA was har-
vested from HBE fi  lters grown at an air  –  liquid interface; 
the filters used were from the same groups used for 
transepithelial current measurements. RNA was also 
harvested from HEK 293 cells transfected with the dif-
ferent constructs used for whole cell electrophysiology 
as controls. The RNA was reverse transcribed, and then 
probed for CFTR and SLC26A9 mRNA expression using 
PCR. As shown in   Fig. 9  , both wt and CF HBE cells dem-
onstrated PCR products for both SLC26A9 and CFTR.   
Transfected HEK 293 cells were positive for SLC26A9 
and CFTR, whereas GFP-transfected control HEK 293 
cells were not. 
  Permeabilization of HBE monolayers reveals the basal 
chloride current 
  Our results in HEK 293 cells suggested that the inhibi-
tory action of GlyH-101 on SLC26A9 could be differen-
tiated from its action on CFTR by comparing the I-V 
relations during blocker application. The complexity of 
the HBE cell monolayer in terms of the known chan-
nels, transporters, and pumps required us to electrically 
isolate the apical membrane and limit permeant bath solu-
tion anions to those used in the whole cell patch clamp 
experiments to perform meaningful I-V comparisons. 
  Figure 9.     RT-PCR indicates that HBE monolayers express SLC26A9 mRNA. (A) RNA harvested from either wt or     F508/    F508 CF 
HBE monolayers grown at air liquid interface for at least 2 wk demonstrates endogenous mRNA for both SLC26A9 (1,100-bp product) 
and CFTR (237-bp product);     -actin was amplifi  ed as a control (353-bp product). Apparent differences in SLC26A9 mRNA between wt 
and CF HBE monolayers were not quantifi  ed. (B) HEK 293 cells were transfected with GFP alone (as control), or GFP and SLC26A9   ±   
wtCFTR, as indicated in Materials and methods and at the bottom of the fi  gure. Control HEK cells do not express endogenous SLC26A9. 
Molecular weights and markers are the same as in A (  n     ≥   3).     432   SLC26A9 IS CONSTITUTIVELY ACTIVE AND REGULATED BY CFTR 
comparison with the chloride currents and their I-V 
characteristics in HEK 293 cells, we performed the re-
mainder of our monolayer measurements in bicarbon-
ate-free solutions. 
      -Toxin has been used to permeabilize membranes 
and isolate the CFTR anion conductance in several 
systems (  Ostedgaard et al., 1992  ;   Hallows et al., 2003  ; 
  Reddy and Quinton, 2003  ). It has the disadvantage of 
The results of   Fig. 1   indicated the possibility of both a 
chloride and bicarbonate component in the basal and/
or stimulated anion effl  ux, and both CFTR (  Smith and 
Welsh, 1992  ;   Poulsen et al., 1994  ;   Devor et al., 1999  ; 
  Krouse et al., 2004  ) and SLC26A9 (  Xu et al., 2005  ) may 
be conductive to bicarbonate under appropriate condi-
tions. With the goal of determining whether SLC26A9 
contributes to the basal currents in HBE monolayers, in 
  Figure 10.         -Toxin  –  permeabilized HBE monolayers exhibit constitutive and forskolin-stimulated chloride currents and voltage-depen-
dent blocker effects. (A) Short-circuit current measurements performed on three separate fi  lters demonstrate GlyH-101 and gliben-
clamide inhibition properties. With a mucosal to serosal chloride gradient of 48 mM (Eq  Cl   =     13 mV), constitutive chloride currents 
from mucosa to serosa were evident after permeabilization, and forskolin stimulation tripled the current. GlyH-101 rapidly inhibited 
the stimulated current (blue trace), whereas glibenclamide inhibition was slower and less effective (black trace). GlyH-101 was equally 
effective at inhibiting the constitutive current before forskolin stimulation (red trace). The forskolin-stimulated current after GlyH-101 
block was small, but forskolin still signifi  cantly shifted the R  IV  , consistent with activation of CFTR (see Results). Bars below the traces in-
dicate additions to the basolateral chamber, whereas those above indicate additions to the apical chamber. Permeabilization with     -toxin 
required     15 min; ouabain was added to inhibit Na-K-ATPase, whereas ATP was added to replenish intracellular stores (  Supplemental 
text  ). Solutions were bicarbonate free, and recordings were started within 2 min of fi  lter submersion. Representative tracings of at least 
four fi  lters per blocker are shown. (B) Same tracings as in A but including the I-V measurements, consisting of bipolar pulses from   ±  10 
to   ±  60 mV in 10-mV steps. Pulses were simultaneously applied to two fi  lters for the traces shown. I-V measurements were performed after 
permeabilization (basal), forskolin stimulation (fsk), and blocker inhibition (fsk+blocker). Although the I-V responses overlapped for 
the basal and fsk measurements, differences in the voltage dependence of the two blockers were evident in the third measurement. Cat-
ion channel blockers (A) were added to minimize contributions from ENaC and potassium channels to the I-V response. The permea-
bilization phase of the recording was removed for clarity. (C) The I-V curves measured for the forskolin-stimulated monolayer treated 
with glibenclamide (black) demonstrate the shift from linear (open symbols) to OR on blocker addition (solid triangles), whereas the 
I-V curves measured for the stimulated monolayer treated with GlyH-101 (blue) demonstrate the shift from linear (open symbols) to IR 
on blocker addition (blue triangles).         Bertrand et al.  433
brane. As shown in   Fig. 10 A  , basolateral addition of 10 
  μ  M forskolin rapidly stimulated an additional chloride 
current to a plateau of 47.1   ±   3.0     A/cm 
2   (  n   = 9), and 
this elevated current was sustained until blocker addi-
tion. The CFTR channel blockers GlyH-101 and glib-
enclamide had signifi  cantly different effects on the 
stimulated chloride current. GlyH-101 rapidly inhibited 
68   ±   9% of Isc within 1 min of application (  n   = 5; P   <   0.01, 
paired test), whereas glibenclamide inhibition was much 
more protracted: only 14   ±   8% (  n   = 4, NS) in the fi  rst 
min and 28   ±   3% after 3 min (P   <   0.01). GlyH-101 inhi-
bition was unchanged after 3 min (69   ±   7%). Thus, 
GlyH-101 was considerably more effective at inhibiting 
the stimulated chloride current. These blocker inhibi-
tion characteristics (kinetics and magnitude) are simi-
lar to those observed in HEK 293 cells coexpressing 
SLC26A9 and CFTR (  Fig. 7 C  ). 
  Having demonstrated the adequacy of permeabilization, 
the presence of both constitutive and forskolin-stimulated 
currents, and blocker actions on forskolin-stimulated 
currents in our permeabilized HBE monolayers, we asked 
the central question: What is the blocker fi  ngerprint for 
HBE constitutive currents? We verifi  ed that GlyH-101 
inhibited the constitutive current in the permeabilized 
HBE monolayers (  Fig. 10 A  ) and measured the I-V rela-
tion during inhibition and after the addition of forskolin. 
GlyH-101 inhibited 68   ±   6% of the basal current, yet the 
R  IV   for this inhibition was essentially linear (0.97   ±   0.01; 
  n   = 8), a strong argument against CFTR as the source 
of this constitutive current (  Table II  ).   Furthermore, al-
though the forskolin-stimulated current in the presence 
of GlyH-101 was small (  Fig. 10 A  ), the corresponding 
R  IV   dropped to 0.89   ±   0.01, a statistically signifi  cant shift 
toward IR (P   <   0.005, paired   t   test;   n   = 8), consistent 
with both the activation of CFTR and the similar re-
sponse of HEK 293 coexpressors. 
  After forskolin stimulation, the different voltage de-
pendencies of the two blockers were evident in the 
skewed amplitudes of the I-V pulse currents (  Fig. 10 B  ). 
The derived I-V curves confi  rmed that the basal and for-
skolin-stimulated I-V relations were essentially linear, 
whereas glibenclamide induced an OR I-V relation and 
GlyH-101 resulted in an IR I-V relation (  Fig. 10 C  ). The 
mean R  IV   values are provided in   Table II  . The basal ratio 
was unchanged by forskolin stimulation, and both were 
slightly OR (1.06). Stimulated monolayers treated with 
creating relatively large pores (1.5 nm;   Bhakdi et al., 
1993  ) that also permit the fl  ux of divalent cations and 
ATP, which requires attention to bath solution composi-
tion. After testing several different doses of     -toxin and 
the impact of ATP loss on the forskolin response of per-
meabilized monolayers (Supplemental text), we adopted 
a permeabilization protocol that included a relatively 
low dose of     -toxin, inhibition of the Na-K-ATPase with 
100   μ  M ouabain (to limit energy use), and addition of 
1 mM Na-ATP, all applied to the basolateral bath. As 
shown in   Fig. 10 A  , complete permeabilization with 
    -toxin required     15 min, as judged by the shift in 
current.   Sequential addition of ouabain and ATP after 
the initial evidence of permeabilization did not alter 
the short-circuit current from that seen in their absence 
(Supplemental text). Apical addition of the cation chan-
nel blockers amiloride and barium chloride had no 
impact on Isc, as expected in the absence of bath solu-
tion cation gradients. 
  The effectiveness of permeabilization was determined 
by comparing the pre- and post-permeabilization basal 
currents using equivalent mucosal to serosal or serosal 
to mucosal chloride gradients. With a mucosal to sero-
sal chloride gradient, monolayers exhibited an initial 
Isc of     16.5   ±   1.3     A/cm 
2   that shifted to +16.3   ±   
1.0     A/cm 
2   (  n   = 19) after permeabilization (  Fig. 10 A  ), 
consistent with the chloride-absorptive current expected 
for this gradient and holding potential (0 mV). With a 
similar but oppositely directed (serosal to mucosal) 
chloride gradient, monolayers exhibited a basal Isc of 
    27.1   ±   1.6     A/cm 
2   (  n   = 12) that dropped to     14.8   ±   2.8 
    A/cm 
2  , consistent with a secretory chloride current. The 
pre-permeabilization currents were statistically different; 
however, only the polarity of the post-permeabilization 
current changed. Furthermore, basolateral addition of 
bumetanide to permeabilized forskolin-stimulated mono-
layers had no effect (not depicted). These results indi-
cated that the basolateral membrane was completely 
permeable to chloride, and the short-circuit current was 
driven solely by the imposed chloride gradient. 
  GlyH-101 and glibenclamide have different inhibition 
characteristics in HBE monolayers 
  These results confi  rmed that HBE monolayers had a 
signifi  cant, constitutively active chloride conductance 
(Isc = 16.3   ±   1.0     A/cm 
2  ) localized to the apical mem-
  TABLE II  
  Comparison of blocker impact on R  IV   for HBE monolayers 
Drug order Basal Forskolin GlyH-101 Forskolin 
  +GlyH-101
Forskolin 
  +Glibenclamide
GlyH-101 
  +Forskolin
Glibenclamide 
  +Forskolin
wtHBE 
    G  P   adjusted     
a   
1.06   ±   0.01 
    1.17   ±   0.06 
1.06   ±   0.02 0.97   ±   0.01 
    0.90   ±   0.05 
0.83   ±   0.03 1.39   ±   0.14 0.89   ±   0.01 
    0.66   ±   0.03 
1.50   ±   0.03
Order of agonist or blocker represents experimental additions. Each measurement represents an   n     ≥   6.
   
a    Values calculated with correction for paracellular conductance.434   SLC26A9 IS CONSTITUTIVELY ACTIVE AND REGULATED BY CFTR 
current suggestive of SLC26A9 expression at the apical 
membrane, we applied the     -toxin permeabilization pro-
tocol to CF HBE. In the presence of a mucosal to serosal 
chloride gradient, the CF epithelia had an initial basal 
current of     5.67   ±   0.56     A/cm 
2   (  n   = 6) that shifted to 
2.38   ±   0.51     A/cm 
2   after permeabilization, signifi  cantly 
less basal current than observed in normal HBE (16.3   ±   
1.0     A/cm 
2  ). This basal current was unaffected by either 
GlyH-101 (107   ±   10% of basal;   n   = 3) or glibenclamide 
(105   ±   6% of basal;   n   = 3), and the I-V relation during 
blocker addition remained mildly IR for both (0.94  ±   0.02 
and 0.93   ±   0.03, respectively). The addition of forskolin 
was without effect on the current, as expected for a lack 
of functional CFTR at the apical plasma membrane. 
Thus, the CF monolayers did not appear to express con-
ductive SLC26A9 or CFTR at the apical membrane. 
  To test whether defective CFTR could suppress or mod-
ify the expression of SLC26A9 at the plasma membrane, 
we coexpressed SLC26A9 and     F508 CFTR in HEK 293 
cells. These     F508 CFTR coexpressors had a basal cur-
rent of     29   ±   5 pA/pF (  n   = 5), but their I-V relations 
matched the R  IV   properties measured for endogenous 
chloride channels in HEK cells (  Table III  ).   This basal cur-
rent rapidly ran down (50   ±   9% in 3 min), consistent with 
observations in HEK cells expressing GFP alone (Supple-
mental text). As shown in   Table III  , cells expressing GFP 
alone maintained an OR R  IV   over time, even though cur-
rent rundown occurred. The same phenomenon was 
observed in the HEK cells coexpressing SLC26A9 with 
    F508 CFTR, even though the cells were exposed to 
forskolin for 3 min. In contrast, cells expressing wtCFTR 
alone transitioned from an OR R  IV   to a linear relation 
with current stimulation on exposure to forskolin. Thus, 
the linear R  IV   fi  ngerprint, typical of SLC26A9 alone or in 
combination with wtCFTR (  Table I  ), was not evident 
when the channel was coexpressed with     F508 CFTR. 
  SLC26A9 immunoprecipitates wtCFTR 
  To confi  rm an interaction between SLC26A9 and wtCFTR 
in vivo, coimmunoprecipitation was performed on HEK 
glibenclamide shifted to an OR R  IV   of 1.39   ±   0.14 (  n   = 3), 
whereas those treated with GlyH-101 had an IR R  IV   of 
0.83   ±   0.03 (  n   = 5). Both ratios were signifi  cantly changed 
from their R  IV   before block (paired   t   test, P   <   0.05). 
Similar to the HEK 293 fi  ndings (  Table I  ), the blocker-
dependent changes in R  IV   were not affected by the or-
der of stimulation versus blocker application (  Table II  ). 
Compared with the R  IV   measured in HEK 293 cells 
(  Table I  ), the degree of nonlinearity was substantially 
less than that observed in cells expressing only wtCFTR, 
and moderately less than HEK 293 cells co  expressing 
SLC26A9 and CFTR. 
  The tendency toward less rectifi  cation in the R  IV   of the 
monolayers for all blocker combinations likely refl  ects 
voltage-independent currents through the paracellular 
pathway. The intact monolayer is of moderate transepi-
thelial resistance, 405   ±   40   Ω  cm 
2  , yielding a conductance 
(G  T  ) of 2.80   ±   0.50 mS/cm 
2   (  n   = 8). After     -toxin permea-
bilization effectively eliminated the resistance of the baso-
lateral membrane, and cation channel blockers were 
added to the apical bath, the recorded G  T   was 4.39   ±   0.85 
mS/cm 
2  , which should primarily refl  ect the conductance 
of SLC26A9 and the paracellular pathway. The addition 
of GlyH-101 to the apical bath to inhibit SLC26A9 re-
duced G  T   to 2.68   ±   0.47 mS/cm 
2  . If this represents 70% 
inhibition of SLC26A9 (  Figs. 5 and 8  ), the paracellular 
pathway accounts for     45% of the total conductance 
of the permeabilized monolayer. To confi  rm this without 
relying on assumed blocker effi  ciency, we estimated G  P   
from a fi  t of Isc under constitutive and GlyH-101  –  blocked 
conditions (see Materials and methods). G  P   was 2.29   ±   0.5 
mS/cm 
2   by this technique, or 50  ±   6% of the recorded G  T  . 
Adjusted R  IV   values based on the apical membrane con-
ductance alone, for monolayers treated with GlyH-101, 
are shown italicized in   Table II   and compare favorably 
with the values observed in HEK coexpressors (  Table I  ). 
  Effect of     F508 CFTR on SLC26A9 current 
  The RT-PCR results revealed expression of SLC26A9 
mRNA in the CF HBE monolayers. To probe for a basal 
  TABLE III  
  Endogenous channel R  IV   fi  ngerprint is evident in SLC26A9 +     F508CFTR coexpressing HEK 293 cells 
Construct Time
60 s 240 s 420 s
GFP 
  (  ±   fsk, n.s.)   
a   
1.27   ±   0.09 1.28   ±   0.09 1.29   ±   0.11
wtCFTR  
  (no fsk)
1.27   ±   0.15 1.36   ±   0.11 nt   
b   
wtCFTR 
  (3 min fsk at 240 s)
1.30   ±   0.05 0.98   ±   0.01   
c   0.95    ±   0.01   
c   
SLC26A9 +     F508CFTR 
  (3 min fsk at 240 s)
1.20   ±   0.05 1.20   ±   0.07 1.27   ±   0.08
   
a    GFP-alone constructs did not demonstrate signifi  cant differences in R  IV   in the presence or absence of forskolin stimulation, and the data are pooled.
   
b    nt, not tested.
   
c    P   <   0.01 compared to same time point in other constructs.    Bertrand et al.  435
appears to require functional CFTR to maintain signifi  -
cant activity at the apical membrane of airway epithelia. 
Finally, our results in the HEK 293 expression system 
show that the coexpression of SLC26A9 and wtCFTR 
confers enhanced forskolin-stimulated chloride currents, 
suggestive of a reciprocal regulatory interaction, as dem-
onstrated between other SLC26A family proteins and 
CFTR (  Ko et al., 2004  ). 
  Establishing a pharmacological ﬁ  ngerprint for SLC26A9 
  Determining a means for differentiating the contribu-
tions of SLC26A9 and CFTR to the chloride secretory 
currents was essential, as there was no defi  nitive identi-
fying feature in the constitutive activity of SLC26A9 ex-
pressed in HEK 293 cells (  Figs. 2  –  5  ) that could be used 
to differentiate it from CFTR in HBE monolayers. Be-
cause GlyH-101 was known to inhibit basal currents in 
airway epithelia (  Wang et al., 2005  ;   Song et al., 2006  ), 
we evaluated its ability to interact with SLC26A9. GlyH-
101 proved to be an effective inhibitor of SLC26A9, 
although the difference in the magnitude of inhibition, 
while statistically signifi  cant, was not suffi  ciently selec-
tive to permit differentiation of the contributions of 
SLC26A9 and CFTR to the currents across airway epi-
thelia. However, the I-V relations during block were 
markedly different. The typical strong IR I-V relation 
seen during GlyH-101 inhibition of CFTR (  Muanprasat 
et al., 2004  ) was nearly absent during its inhibition of 
SLC26A9 (  Fig. 4 B  ). We calculated the ratio of the cur-
rents (R  IV  ) to quantify the degree of nonlinearity in the 
I-V relations. The R  IV   values in   Table I   document the 
signifi  cant differences noted for SLC26A9 and CFTR. 
Thus, measurement of R  IV   during blocker application 
provided the needed fi  ngerprint to examine the behav-
ior of HEK 293 cells coexpressing SLC26A9 and CFTR, 
and ultimately HBE. 
  Coexpression of SLC26A9 with CFTR in HEK 293 cells 
  Cells coexpressing SLC26A9 and CFTR had both con-
stitutive currents and enhanced currents in response to 
cAMP stimulation, as quantifi  ed during and after expo-
sure to the cAMP agonist, forskolin (  Fig. 6 D  ). Before 
forskolin stimulation, the magnitude of the constitutive 
current and the GlyH-101 inhibition fi  ngerprint in co-
expressors were indistinguishable from the responses 
measured for SLC26A9 alone (  Fig. 5   and   Table I  ), sug-
gesting that the channels were acting independently 
in the absence of cAMP/PKA stimulation. In studies 
of the interaction between the electrogenic exchanger 
SLC26A3 or A6 and CFTR (  Dorwart et al., 2008  ), pH 
measurements indicated that the exchangers were func-
tional in the absence of stimulation, and CFTR activation 
enhanced not only the open probability (Po) of CFTR, 
but also the anion exchange rate of these SLC26A trans-
porters. In our studies, the magnitude of the currents 
observed during forskolin stimulation in the   coexpressors 
293 cells transiently transfected with wtCFTR   ±   myc-
tagged SLC26A9. As shown in   Fig. 11  , anti-myc precipi-
tated both immature (band B) and mature (band C) 
wtCFTR from HEK 293 cells coexpressing both channels, 
confi  rming that an interaction exists between SLC26A9 
and CFTR in vivo.   Interestingly, the interaction between 
immature CFTR and myc-SLC26A9 may provide an ex-
planation for our fi   nding that constitutive SLC26A9 
currents were not detected in either CF HBE or HEK 
293 cells coexpressing SLC26A9 with     F508 CFTR. As 
this mutation blocks the maturation and plasma mem-
brane expression of CFTR (  Cheng et al., 1990  ), their 
interaction may also lead to the intracellular retention 
of SLC26A9. 
  DISCUSSION  
  Signifi  cant, constitutive chloride secretion has been de-
tected in the airways (e.g.,   Figs. 1 and 10  ), and this con-
stitutive activity has been attributed to CFTR due to its 
absence in airway epithelia from CF patients as well as 
its partial inhibition by specifi  c CFTR channel blockers. 
However, a mechanism for basal CFTR activity in the 
absence of added agonists has not been forthcoming. 
Our results have demonstrated that SLC26A9 exhibits 
the properties previously attributed to the constitutive 
activity of CFTR: it is active in the absence of cAMP/
PKA-dependent agonists, it conducts chloride and con-
tributes to transepithelial chloride currents, it displays 
linear I-V characteristics, and it is signifi  cantly inhibited by 
the CFTR pore blocker, GlyH-101. Furthermore, SLC26A9 
  Figure 11.     SLC26A9 interacts with wtCFTR in vivo. Equal 
amounts of protein (    500   μ  g) from HEK 293 cells transiently 
transfected with wtCFTR alone or with CFTR plus myc-SLC26A9 
(myc-A9) were subjected to IP with anti-myc antibodies (left). Of 
the total protein used for IP (left), 10% was used as input (right); 
this and coprecipitated CFTR were detected by immunoblot. 
SLC26A9 was detected by immunoblot with anti-myc; the doublet 
shown has been previously detected for both myc- and HA-tagged 
SLC26A9 (  Dorwart et al., 2007  ). An immunoblot of actin was per-
formed as a loading control (separate blot). Representative blots 
of three experiments are shown.     436   SLC26A9 IS CONSTITUTIVELY ACTIVE AND REGULATED BY CFTR 
To probe the I-V relations of the monolayers against the 
blocker fi  ngerprint identifi  ed in HEK 293 cells, it was 
necessary to electrically isolate the apical membrane. 
We optimized an     -toxin permeabilization protocol 
(Supplemental text) that left the basolateral membrane 
completely permeable to chloride, as assessed by reversing 
the chloride gradient direction, while leaving the mono-
layers responsive to forskolin stimulation (  Fig. 10  ). 
Similar to the intact monolayer (  Fig. 1  ), GlyH-101 blocked 
the constitutive chloride current in permeabilized HBE 
monolayers (  Fig. 10 A  ), and the R  IV   during inhibition 
remained linear (  Table II  ). After GlyH-101 inhibition, 
the addition of forskolin resulted in only a small in-
crease in current, but the R  IV   nonetheless shifted sig-
nifi  cantly to IR (  Table II  ), consistent with activation of 
CFTR and confi  rming that the properties of the consti-
tutive current were like those of SLC26A9. 
  The degree of nonlinearity was mild and more closely 
matched the results from HEK cells coexpressing SLC26A9 
and wtCFTR than those expressing CFTR alone. The 
reduced degree of nonlinearity for all monolayer R  IV   
measurements (  Table II  ) as compared with the same 
protocols in HEK 293 cells (  Table I  ) appears to refl  ect 
the I-V properties of the paracellular pathway because 
values quite similar to those observed in the HEK co-
expressors were noted (  Tables I and II  ) after subtrac-
tion of the estimated paracellular current component. 
In particular, the shift toward IR observed on the addi-
tion of forskolin to GlyH-101  –  inhibited monolayers was 
amplifi  ed after adjustment for G  P  . 
  Potential blocker variability 
  One concern with the use of blocker response as a chan-
nel identifi  er in these assays is that the blocker effective-
ness could be modifi  ed by the interaction between 
CFTR and SLC26A9. First, we note that earlier studies 
using glibenclamide demonstrated that it was equally ef-
fective at inhibiting the forskolin-stimulated currents in 
HEK cells expressing CFTR alone as in cells coexpress-
ing electrogenic SLC26A transporters and CFTR (  Ko 
et al., 2004  ), and at the same concentration used in our 
studies. Second, we demonstrated that GlyH-101 inhibi-
tion of the poststimulation current in HEK 293 cells 
  coexpressing both CFTR and SLC26A9 (  Fig. 8  ) results 
in the same R  IV   and magnitude of inhibition as seen in 
cells expressing SLC26A9 alone (  Fig. 4 A   and   Table I  ), 
even though this current required CFTR stimulation. 
Thus, the properties of GlyH-101 inhibition of SLC26A9 
would not appear to be altered by its functional inter-
action with CFTR. Third, the changes in R  IV   in HEK 293 
cells (  Table I  ) and HBE monolayers (  Table II  ) support 
a shift toward greater IR upon activation of CFTR in the 
presence of GlyH-101, consistent with CFTR contribut-
ing the greater nonlinearity. Finally, the R  IV   values mea-
sured in HEK cells coexpressing SLC26A9 plus CFTR 
are the approximate averages of the values measured in 
exceeded the sum of the currents measured from 
SLC26A9 and CFTR expressed separately (  Fig. 6 D  ), 
suggesting that activation of CFTR indeed promoted 
functional channel interactions. Furthermore, coimmu-
noprecipitation experiments ( Fig. 11 ) confi  rmed a physi-
cal interaction between these proteins in vivo. Thus, our 
results were consistent with these earlier observations. 
  To identify whether the activity of both channels in-
creased during their stimulation-induced functional inter-
action, as noted above for SLC26A3/6, we looked to the 
blocker results. Interestingly, binding of the STAS domain 
of these SLC26A transporters to the phosphorylated R 
domain was shown to increase the Po of CFTR 2.2-fold 
(  Ko et al., 2004  ). This magnitude of increase in CFTR ac-
tivity alone could account for the enhanced forskolin-stim-
ulated current of the SLC26A9 and CFTR   coexpressors. 
Application of GlyH-101 during the forskolin-stimulated 
current plateau shifted the I-V relation from linear to IR 
(  Fig. 7  ), but cells coexpressing SLC26A9 + CFTR dem-
onstrated signifi  cantly less nonlinearity than cells ex-
pressing CFTR alone (  Fig. 7, B and D  , and   Table I  ). Also, 
the magnitude of current inhibition in the coexpressors 
(65%) was signifi  cantly less than that observed for inhi-
bition of CFTR alone (90%), and was not different from 
the inhibition of SLC26A9 alone (71%). These results 
indicated that current fl  owed through both SLC26A9 
and CFTR during stimulation. If the enhanced response of 
the stimulated coexpressors was due entirely to an increase 
in the Po of CFTR, we would expect the magnitude of 
GlyH-101 inhibition and its R  IV   properties to mirror the 
properties observed for CFTR alone because the prestimu-
lation current for SLC26A9 was relatively small (  Fig. 6 D  ). 
Rather, the GlyH-101 inhibition results support a role for 
increased activity of SLC26A9 during CFTR stimulation. 
  Additional evidence that SLC26A9 activity was modi-
fi  ed by an interaction with stimulated CFTR was pro-
vided by the enhanced poststimulation currents that 
persisted after forskolin washout (  Fig. 6 A  ). As shown in 
  Fig. 8  , GlyH-101 effectively blocked the poststimulation 
current, and the inhibition magnitude and kinetics were 
similar to its actions on SLC26A9 alone (  Fig. 4 A  ). Fur-
thermore, the R  IV   for this inhibition was identical to that 
of SLC26A9 alone (  Table I  ), suggesting that the enhanced 
poststimulation current was due entirely to SLC26A9. 
This current could result from increased SLC26A9 activity 
(Po) maintained by a continued interaction with CFTR 
after R domain dephosphorylation, or from the recruit-
ment of additional SLC26A9 channels to the membrane 
during forskolin stimulation in the presence of CFTR. 
Either mechanism depends on CFTR stimulation, so 
that a lack of functional CFTR would impact SLC26A9 
currents at the plasma membrane. 
  HBE responses reﬂ  ect SLC26A9 properties 
  HBE cells harvested from both non-CF and CF donors 
expressed mRNA for both SLC26A9 and CFTR (  Fig. 9  ).     Bertrand et al.  437
native tissues, such as human trachea (  Smith and Welsh, 
1992  ), bronchus (  Coakley et al., 2003  ), and nasal (  Paradiso 
et al., 2003  ) surface epithelium, porcine trachea and 
small airway epithelia (  Wang et al., 2005  ), porcine and 
human submucosal glands (  Song et al., 2006  ), and the 
serous cell submucosal gland cell line Calu-3 (  Krouse 
et al., 2004  ). In all cases, these currents have been attrib-
uted to spontaneous activity of CFTR. These observa-
tions, combined with our fi  ndings, suggest that SLC26A9 
contributes signifi  cantly to constitutive anion secretion 
by both airway gland and surface epithelia, and thus 
may be an important modulator of ASL volume and 
pH regulation. The absence of constitutive currents in 
tissues from CF patients, together with our data sug-
gesting that SLC26A9 is not functional at the plasma 
membrane when coexpressed with     F508-CFTR, im-
plies that SLC26A9 contributes to the airway pathology 
observed in CF. 
  Members of the SLC26A family are found in all epi-
thelia known to express CFTR, and they demonstrate a 
diverse range of functions that appear to be specifi  c for 
the physiological requirements of the organ systems 
where they are expressed: bicarbonate transport in the 
pancreas and intestine, acid regulation in the gastric 
parietal cells, and as demonstrated here, constitutive 
chloride secretion in the airway. As a family of transport 
proteins whose functions coordinate with the activity of 
CFTR, they support the hypothesis of CFTR as a trans-
membrane conductance regulator. 
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